Security
MAIA Biotechnology, Inc. · MAIA
MAIANYSE_AMERICANCommon stockCurrentCIK 1878313Updated Nov 11, 2026
MAIA price & chart
Loading TradingView…
AMEX:MAIA on TradingView ↗About the company
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
In the news
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 11,782,021Source | 9,242,842Source | 28,240,171Source | 11,045,854Source | 12,019,608Source | 35,322,645Source | 11,864,652Source | 8,716,036Source | 9,704,656Source | 10,155,279Source | 7,566,852Source | 12,022,040Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Assets, CurrentUSD | 11,754,936Source | 9,240,042Source | 28,237,371Source | 11,043,054Source | 12,016,808Source | 35,315,127Source | 11,861,852Source | 8,700,001Source | 9,701,856Source | 10,152,479Source | 7,564,052Source | 11,808,037Source |
| Prepaid Expense and Other Assets, CurrentUSD | 780,515Source | 495,650Source | 641,540Source | 816,260Source | 259,730Source | 902,017Source | 920,472Source | 272,583Source | 1,043,825Source | 473,834Source | 268,677Source | 554,321Source |
| Other Assets, NoncurrentUSD | 27,085Source | 2,800Source | 2,800Source | 2,800Source | 2,800Source | 7,518Source | 2,800Source | 2,800Source | 2,800Source | 2,800Source | 2,800Source | 2,800Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,740,351Source | 7,624,251Source | 7,565,161Source | 7,169,170Source | 8,857,713Source | 7,559,877Source | 6,922,127Source | 14,480,964Source | 7,328,793Source | 6,520,643Source | 7,089,341Source | 3,514,247Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,446Source | 2,397Source | 6,082Source | 3,182Source | 2,374Source | 6,068Source | 2,959Source | 2,059Source | 3,863Source | 2,616Source | 1,699Source | 1,096Source |
| Additional Paid in CapitalUSD | 106,071,303Source | 85,290,791Source | 144,654,861Source | 101,002,585Source | 84,108,607Source | 143,797,024Source | 96,729,813Source | 66,310,691Source | 112,053,233Source | 90,897,468Source | 64,472,249Source | 52,729,942Source |
| Retained Earnings (Accumulated Deficit)USD | -106,002,244Source | -83,662,895Source | -123,944,244Source | -97,099,055Source | -80,926,908Source | -116,000,657Source | -91,752,092Source | -72,047,632Source | -109,631,005Source | -87,234,833Source | -63,980,177Source | -44,207,272Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -30,835Source | -11,702Source | -41,689Source | -30,028Source | -22,178Source | -39,667Source | -38,155Source | -30,046Source | -50,228Source | -30,615Source | -16,260Source | -15,973Source |
| Stockholders' Equity Attributable to ParentUSD | 41,670Source | 1,618,591Source | 20,675,010Source | 3,876,684Source | 3,161,895Source | 27,762,768Source | 4,942,525Source | — | 2,375,863Source | — | — | — |
| Liabilities and EquityUSD | 11,782,021Source | 9,242,842Source | 28,240,171Source | 11,045,854Source | 12,019,608Source | 35,322,645Source | 11,864,652Source | 8,716,036Source | 9,704,656Source | 10,155,279Source | 7,566,852Source | 12,022,040Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,994,444Source | 3,608,899Source | 6,257,892Source | 5,043,952Source | 3,511,075Source | 6,322,437Source | 5,057,511Source | 4,907,767Source | 5,836,398Source | 3,830,038Source | 4,937,153Source | 3,268,906Source |
| Accounts Payable, CurrentUSD | 3,175,641Source | 1,152,055Source | 2,838,652Source | 1,723,163Source | 1,263,788Source | 2,983,058Source | 1,841,369Source | 1,872,502Source | 2,038,803Source | 1,512,436Source | 1,638,546Source | 1,165,505Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 6,818,803Source | 2,456,844Source | 3,419,240Source | 3,320,789Source | 2,247,287Source | 3,339,379Source | 3,216,142Source | 3,035,265Source | 3,797,595Source | 2,317,602Source | 3,298,607Source | 2,103,401Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -2,735,987Source | — | — | — | -4,517,259Source | — | -23,254,656Source | -19,772,905Source | -15,769,279Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 650,024Source | 371,472Source | 2,631,652Source | 1,912,744Source | 3,089,304Source | 2,319,427Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 940,877Source | 359,070Source | 519,720Source | -118,827Source | 471,897Source | 211,346Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,311,328Source | -4,202,274Source | -18,844,598Source | -15,704,461Source | -13,071,016Source | -11,655,725Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 31,052,321Source | 5,461,216Source | 17,906,547Source | 18,176,609Source | 9,270,901Source | 12,036,790Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | 1,261,998Source | — | 2,450,603Source | -3,800,232Source | 376,635Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 8,690,784Source | — | — | — | 10,863,296Source | — | 9,601,298Source | 7,150,695Source | 10,950,927Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 646,900Source | 455,388Source | 723,915Source | 802,484Source | 650,024Source | 371,472Source | 2,631,652Source | 1,912,744Source | 3,089,303Source | 2,319,427Source |
| General and Administrative ExpenseUSD | — | — | 3,003,636Source | 1,521,298Source | 2,677,591Source | 2,055,191Source | 3,424,832Source | 2,227,899Source | 9,722,354Source | 6,947,981Source | 9,070,124Source | 6,143,527Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 339Source | 0Source | 2,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 106,082Source | — | 79,697Source | — | 82,183Source | — | 318,367Source | 34,490Source | 1,870Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,903,189Source | -2,735,987Source | -7,943,587Source | -5,346,963Source | -6,369,652Source | -4,517,259Source | -22,396,172Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,903,189Source | -2,735,987Source | -7,943,587Source | -5,346,963Source | -6,369,652Source | -4,517,259Source | -22,396,172Source | -23,254,656Source | -19,772,905Source | -16,219,857Source |
| Operating ExpensesUSD | — | — | 9,360,926Source | 4,188,468Source | 8,317,251Source | 5,166,058Source | 6,949,929Source | 5,425,431Source | 24,269,686Source | 16,957,210Source | 20,182,381Source | 16,176,201Source |
| Other Operating Income (Expense), NetUSD | — | — | 457,737Source | 1,452,481Source | — | -180,905Source | — | 908,172Source | 1,873,514Source | -6,297,446Source | 409,476Source | 406,922Source |
| Proceeds from Issuance of Common StockUSD | — | — | 117,136Source | 63,810Source | — | — | — | 1,521,091Source | 327,615Source | — | — | 2,473,560Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 38,549Source | 844Source | 844Source | 217,158Source | 1,432Source | 84,000Source |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -9,360,926Source | -4,188,468Source | -8,317,251Source | -5,166,058Source | -6,949,929Source | -5,425,431Source | -24,269,686Source | -16,957,210Source | -20,182,381Source | -16,176,201Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -22,392,000Source | -23,300,000Source | -19,800,000Source | -15,800,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 339Source | 0Source | 2,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,903,189Source | -2,735,987Source | -7,943,587Source | -5,346,963Source | -6,369,652Source | -4,517,259Source | -22,396,172Source | — | — | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.27Source | -0.11Source | -0.13Source | -0.18Source | -0.14Source | -0.16Source | -0.7Source | -1.05Source | -1.49Source | -1.75Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.27Source | -0.11Source | -0.13Source | -0.18Source | -0.14Source | -0.16Source | -0.7Source | -1.05Source | -1.49Source | -1.75Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 33,202,001Source | 23,894,980Source | 60,794,335Source | 30,300,339Source | 45,212,103Source | 27,696,550Source | 32,114,608Source | 22,197,517Source | 13,261,572Source | 9,276,761Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 33,202,001Source | 23,894,980Source | 60,794,335Source | 30,300,339Source | 45,212,103Source | 27,696,550Source | 32,114,608Source | 22,197,517Source | 13,261,572Source | 9,276,761Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,003,636Source | 1,521,298Source | 2,677,591Source | 2,055,191Source | 3,424,832Source | 2,227,899Source | 9,722,354Source | 6,947,981Source | 9,070,124Source | 6,143,527Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -22,181,000Source | — | -19,600,000Source | -15,300,000Source |
| Interest ExpenseUSD | — | — | — | 85Source | — | — | — | — | — | 57Source | 6,863Source | 6,967Source |
| Investment Income, InterestUSD | — | — | — | 106,082Source | — | 79,697Source | — | 82,183Source | — | 318,367Source | 34,490Source | 1,870Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,903,189Source | -2,735,987Source | -7,943,587Source | -5,346,963Source | -6,369,652Source | -4,517,259Source | -22,396,172Source | -23,254,656Source | -19,772,905Source | -16,219,857Source |
| Operating ExpensesUSD | — | — | 9,360,926Source | 4,188,468Source | 8,317,251Source | 5,166,058Source | 6,949,929Source | 5,425,431Source | 24,269,686Source | 16,957,210Source | 20,182,381Source | 16,176,201Source |
| Other Operating Income (Expense), NetUSD | — | — | 457,737Source | 1,452,481Source | — | -180,905Source | — | 908,172Source | 1,873,514Source | -6,297,446Source | 409,476Source | 406,922Source |
| Research and Development ExpenseUSD | — | — | — | 2,667,170Source | — | — | 43,651Source | 3,197,532Source | 453,745Source | 10,009,229Source | 11,112,257Source | 8,933,314Source |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299148
Registration 333-298486
Filing attachments
ex107.htm · S-3 · 2026-09-25
Calculation of Filing Fee Tables S-3 MAIA Biotechnology, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offe…
Read attachment ↗ex107.htm · S-3 · 2026-08-21
Calculation of Filing Fee Tables S-3 MAIA Biotechnology, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggre…
Read attachment ↗ex4-3.htm · S-3 · 2026-08-21
Exhibit 4.3 MAIA BIOTECHNOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF, 20 SENIOR DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions 4 of Terms ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION 7 AND EXCHANGE OF SECURITIES Section 2.…
Read attachment ↗ex4-4.htm · S-3 · 2026-08-21
Exhibit 4.4 MAIA BIOTECHNOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF, 20 SUBORDINATED DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions 4 of Terms ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION 7 AND EXCHANGE OF SECURITIES Sect…
Read attachment ↗